Clinical Trial Update: Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas [Phase 2]

View source ↗

Summary

A Phase 2 trial of crenolanib for adult gliomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Glioma | Phase 2 | Status: TERMINATED